These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 35797378)

  • 1. A structured framework for adaptively incorporating external evidence in sequentially monitored clinical trials.
    Kwiatkowski E; Andraca-Carrera E; Soukup M; Psioda MA
    J Biopharm Stat; 2022 May; 32(3):474-495. PubMed ID: 35797378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bayesian adaptive design for pediatric clinical trials incorporating a community of prior beliefs.
    Wang Y; Travis J; Gajewski B
    BMC Med Res Methodol; 2022 Apr; 22(1):118. PubMed ID: 35448963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Bayesian Hybrid Adaptive Randomisation Design for Clinical Trials with Survival Outcomes.
    Moatti M; Chevret S; Zohar S; Rosenberger WF
    Methods Inf Med; 2016; 55(1):4-13. PubMed ID: 26404511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Bayesian and frequentist group-sequential clinical trial designs.
    Stallard N; Todd S; Ryan EG; Gates S
    BMC Med Res Methodol; 2020 Jan; 20(1):4. PubMed ID: 31910813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simulating and reporting frequentist operating characteristics of clinical trials that borrow external information: Towards a fair comparison in case of one-arm and hybrid control two-arm trials.
    Kopp-Schneider A; Wiesenfarth M; Held L; Calderazzo S
    Pharm Stat; 2024; 23(1):4-19. PubMed ID: 37632266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Bayesian approach in design and analysis of pediatric cancer clinical trials.
    Ye J; Reaman G; De Claro RA; Sridhara R
    Pharm Stat; 2020 Nov; 19(6):814-826. PubMed ID: 32537913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utility of propensity score-based Bayesian borrowing of external adult data in pediatric trials: A pragmatic evaluation through a case study in acute lymphoblastic leukemia (ALL).
    Majumdar A; Rothwell R; Reaman G; Ahlberg C; Roy P
    J Biopharm Stat; 2023 Nov; 33(6):737-751. PubMed ID: 36600441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modeling of experts' divergent prior beliefs for a sequential phase III clinical trial.
    Moatti M; Zohar S; Facon T; Moreau P; Mary JY; Chevret S
    Clin Trials; 2013 Aug; 10(4):505-14. PubMed ID: 23820061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bayesian selective response-adaptive design using the historical control.
    Kim MO; Harun N; Liu C; Khoury JC; Broderick JP
    Stat Med; 2018 Nov; 37(26):3709-3722. PubMed ID: 29900577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A practical guide to Bayesian group sequential designs.
    Gsponer T; Gerber F; Bornkamp B; Ohlssen D; Vandemeulebroecke M; Schmidli H
    Pharm Stat; 2014; 13(1):71-80. PubMed ID: 24038922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An adaptive power prior for sequential clinical trials - Application to bridging studies.
    Ollier A; Morita S; Ursino M; Zohar S
    Stat Methods Med Res; 2020 Aug; 29(8):2282-2294. PubMed ID: 31729275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation.
    Lewis RJ; Lipsky AM; Berry DA
    Clin Trials; 2007; 4(1):5-14. PubMed ID: 17327241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bayesian design of single-arm phase II clinical trials with continuous monitoring.
    Johnson VE; Cook JD
    Clin Trials; 2009 Jun; 6(3):217-26. PubMed ID: 19528131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bayesian semiparametric meta-analytic-predictive prior for historical control borrowing in clinical trials.
    Hupf B; Bunn V; Lin J; Dong C
    Stat Med; 2021 Jun; 40(14):3385-3399. PubMed ID: 33851441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statistical rules for safety monitoring in clinical trials.
    Martens MJ; Logan BR
    Clin Trials; 2024 Apr; 21(2):152-161. PubMed ID: 37877375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bayesian randomized clinical trials: From fixed to adaptive design.
    Yin G; Lam CK; Shi H
    Contemp Clin Trials; 2017 Aug; 59():77-86. PubMed ID: 28455232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A group-sequential randomized trial design utilizing supplemental trial data.
    Kotalik A; Vock DM; Hobbs BP; Koopmeiners JS
    Stat Med; 2022 Feb; 41(4):698-718. PubMed ID: 34755388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bayesian survival analysis in clinical trials: What methods are used in practice?
    Brard C; Le Teuff G; Le Deley MC; Hampson LV
    Clin Trials; 2017 Feb; 14(1):78-87. PubMed ID: 27729499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A frequentist approach to dynamic borrowing.
    Li R; Lin R; Huang J; Tian L; Zhu J
    Biom J; 2023 Oct; 65(7):e2100406. PubMed ID: 37189217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of local and nonlocal priors in Bayesian test-based monitoring for single-arm phase II clinical trials.
    Zhou Y; Lin R; Lee JJ
    Pharm Stat; 2021 Nov; 20(6):1183-1199. PubMed ID: 34008317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.